Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-27T02:05:41.120Z Has data issue: false hasContentIssue false
  • English
  • Français

Cardiazol Treatment of Schizophrenia

Published online by Cambridge University Press:  19 February 2018

Arthur Harris
Arthur Harris*
Affiliation:
Bexley Hospital (L.C.C.), Kent; West End Hospital Child Guidance Clinic
Get access Rights & Permissions [Opens in a new window]

Extract

The term “schizophrenia” was first introduced by Bleuler (1) as descriptive of the dissociation and fragmentation of mental processes which he regarded as the chief characteristic of the condition. There is “a detachment from the world without, and a breaking up of normal psychological connections within. The personality is not integrated as in normal people; thinking emotion, and conduct are discrepant and morbid, yet there is no impairment of formal intelligence such as is found, for example, in organic dementia” (Mapother and Lewis (2)). To quote Bleuler (1), “even though we cannot as yet formulate a natural division within the disease, nevertheless schizophrenia does not appear to us as a disease in the narrower sense but as a disease group, about analogous with the group of the organic dementias, which are divided into paresis, senile forms, etc. One should therefore speak of schizophrenias in the plural. The disease at times runs a chronic course, at times in shifts; it may become stationary at any stage or may regress a certain distance, but probably does not permit of a complete restitutio ad integrum. It is characterized by a specific kind of alteration of thinking and feeling, and of the relations with the outer world that occur nowhere else”.

Type
Part I.—Original Articles
Information
Journal of Mental Science , Volume 84 , Issue 352 , September 1938 , pp. 735 - 775
Copyright
Copyright © Royal College of Psychiatrists, 1938 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Bleuler, E.—Textbook of Psychiatry, George Allen & Unwin, Ltd., London, 1924.Google Scholar
2 Mapother, E., and Lewis, A.—“Psychological Medicine,” Section 21 of A Textbook of the Practice of Medicine, edited by Price, F. W. Oxford University Press, 1937.Google Scholar
3 Schmidt, K. F., Hildebrandt, F., and Krehl, L.—“Über ‘Cardiazol’, ein in wasseriger Lösung subcutan injizierbares neues Analepticum,” Klin. Wochenschr., 1925, iv, p. 1678.CrossRefGoogle Scholar
4 Ruef, H.—“Über klinische Erfahrungen mit Cardiazol,” ibid., 1925, iv, p. 1680.Google Scholar
5 Hinricks, . —“Cardiazol,” Munch, med. Wochenschr., 1925, lxxii, p. 2102.Google Scholar
6 Hemmerling, H.—“Klinische Erfahrungen mit dem neuen Analeptikum Cardiazol,” Deutsch. med. Wochenschr., 1925, li, p. 1618.Google Scholar
7 Kaiser, K.—“Über Cardiazol,” ibid., 1926, lii, p. 236.Google Scholar
8 Pichler, G.—“Über Cardiazol,” Wien. klin. Wochenschr., 1926, xxxix, p. 964.Google Scholar
9 Lange, F.—“Erfahrungen mit Cardiazol und Hexeton,” Deutsch, med. Wochenschr., 1926, lii, p. 272.Google Scholar
10 Feriz, H.—“Over ervaringen met nieuwe analeptica in de chirurgie,” Nederl. Tijdschr. v. Geneesk., 1926, lxx, p. 1890.Google Scholar
11 Waldbott, G. L.—“Cardiazol, a Heart Stimulant,” Med. Journ. Rec., 1926, cxxiii, p. 821.Google Scholar
12 Henderson, V. E., and Sparks, M. J.—“Recent Respiratory Stimulants,” Univ. of Toronto Med. Journ., 1927, p. 184.Google Scholar
13 Hildebrandt, F.—“Pentamethylenetetrazol (Cardiazol),” Arch. f. exp. Path. u. Pharm., 1926, cxvi, p. 100.Google Scholar
14 Idem. —“Pharmakologie der Kreislaufanaleptica,” ibid., 1936, clxxxi, p. 89.Google Scholar
15 Strube, H.—“Pentamethylenetetrazol (Cardiazol),” ibid., 1927, cxxi, p. 94.Google Scholar
16 Sanders, R.—“Zur Dynamik des Froschherzens. Die Wirkung von Strophanthin, Coffein, Kampfer und Cardiazol,” ibid., 1927, cxxv, p. 358.Google Scholar
17 Fahrenkamp, K.—“Die Verstärkung der systolischen Wirkung der Digitalis-glykoside. durch Cardiazol und Coramin,” ibid., 1928, cxxix, p. 52.Google Scholar
18 Idem. —“Die Verstärkung der Digitaliswirkung durch kampferähnlichwirkende Substanzen,” Med. Klin., 1927, xxiii, No. 1, p. 349.Google Scholar
19 Stross, W.—“Untersuchungen über die Wirkungsweise einiger Analeptika,” Arch. f. exp. Path. u. Pharm., 1926, cxvi, p. 110.Google Scholar
20 Camp, W. J. R.—“The Pharmacology of Cardiazol,” Journ. Pharmacol. Exper. Therap., L928, xxxiii, p. 81.Google Scholar
21 Gremels, H.—“Über die Kreislaufwirkung einiger neuerer Analeptika,” Arch. f. exp. Path. u. Pharm., 1930, clin, p. 36.Google Scholar
22 Idem. —“Über die Einwirkung einiger zentral-erregender Mittel auf Atmung und Kreislauf,” ibid., 1931, clxii, p. 29.Google Scholar
23 Leyko, E.—“The Action of some Heart Tonics,” Journ. Pharmacol, and Exper. Therap., 1930, xxxviii, p. 31.Google Scholar
24 Barker, M. H., and Levine, S. A.—“Cardiazol: Some Experimental Effects of this Drug on the Cardip-respiratory Mechanism,” Arch. Int. Med., 1928, xlii, No. 1, p. 14.Google Scholar
25 Helaers, E.—“Contribution à l'étude de divers analeptiques respiratoires chez le lapin normal ou intoxiqué par la morphine ou le somnifène,” Arch. Internat, de Pharmacodyn. et de Thérapie, 1929, xxxv, p. 221.Google Scholar
26 Schubel, K., and Gehlen, W.—“Vergleichende Untersuchungen über atmungserregende Pharmaka am Morphinvergiftete Kaninchen,” Arch. f. exp. Path. u. Pharm., 1928, cxxxiii, p. 295.Google Scholar
27 Adam, D.—“Über die Herabsetzung der Chloralhydratmortalität durch Cardiazol,” ibid., 1932, clxviii, p. 171.Google Scholar
28 Buding, E. S.—“Zur Systematik des Cardiazols,” ibid., 1930, clvii, p. 143.Google Scholar
29 Tartler, O. P.—“Über den Antagonismus und Synergismus zwischen einigen Analepticis und Medinal,” ibid., 1929, cxliii, p. 65.Google Scholar
30 Kohn, R., and Jacobi, M.—“Untersuchungen über qualitative und quantitative Beziehungen zwischen Schlafmitteln und Analepticis,” ibid., 1935, clxxix, p. 448.Google Scholar
31 Maloney, A. H., and Tatum, A. L.—“Cardiazol (Metrazol) and Coramine as Cardiorespiratory Stimulants,” Arch. Internat, de Pharmacodyn. et de Thérapie, 1932, xlii, p. 200.Google Scholar
32 Maloney, A. H.—“Analysis of the Stimulant-depressant Action of Caffeine, Coramine and Metrazol (Cardiazol) Based on Experimental Data,” ibid., 1936, lii, p. 373.Google Scholar
33 Tinnitz, F., and von Bergman, F.—“Über Kumulierung und Toxizität von Cardiazol und Coramin,” Arch. f. exp. Path. u. Pharm., 1936, clxxxi, p. 335.Google Scholar
34 Blume, W.—“Über die Wirkung des Kampfers und einiger Kampferersatzpräparate auf das Rückenmark der dekapitierten Katze,” ibid., 1926, cxvi, p. 234.Google Scholar
35 Knoefel, P. K., and Murrel, F. C.—“The Action of some Stimulants on Spinal Reflexes,” Arch. Internat, de Pharmacodyn. et de Thérapie, 1935, lii, p. 49.Google Scholar
36 Muskens, L. W.—Epilepsy, Baillière, Tindall & Cox, London, 1928.Google Scholar
37 Fulton, J. F., and Keller, A. D.—“The Sign of Babinski: A Study of the Evolution of Cortical Dominance in Primates,” ibid., 1932.CrossRefGoogle Scholar
38 Idem —“Observations on the Response of the Same Chimpanzee to Dial, Amytal and Nembutal used as Surgical Anaesthetics,” Surg. Gynec. Obst., 1932, liv, p. 764.Google Scholar
39 Silver, S.—“Über die Schmerzüberempfindlichkeit durch Schlafmittel und ihre Beeinflussung,” Arch. f. exp. Path. u. Pharm., 1930, clviii, p. 219.Google Scholar
40 Behrens, B., and Reichelt, E.—“Vergleich von Cardiazol und Coramin in Tierexperiment,” Klin. Wochenschr., 1933, xii, p. 1860.Google Scholar
41 Steiniger, H., and Gaubatz, E.—“Vergleich der Wirkung von Cardiazol und Coramin auf das Atemzentrum des Menschen,” ibid., 1935, xiv, pp. 159 and 827.Google Scholar
42 Hicks, C. S.—“A Note on the Comparison of the Action of Metrazol and Coramine on the Respiratory Centre of Man,” Australian Journ. Exp. Biol, and Med. Sci., 1935, xiii, p. 261.CrossRefGoogle Scholar
43 Muller, E. A.—“Die Wirkung des Cardiazols auf Atmung und Gasstoffwechsels in der Pernoctonnarkose,” Med. Klin., 1936, xxxii, p. 495.Google Scholar
44 Eichler, C., and Hildebrandt, F.—“Pentamethylenetetrazol (Cardiazol),” Arch. f. exp. Path. u. Pharm., 1926, cxvi, p. 110.Google Scholar
45 Schoen, R.—“Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe,” ibid., 1926, cxiii, p. 275.Google Scholar
46 Mehl, W.—“Addition der Wirkung von einiger Analepticis zu Medinal,” ibid., 1930, cli, p. 41.Google Scholar
47 Philips, H.—“The Effect of Stimulants on Drug Poisoning,” Med. Journ. Record, 1930, cxxxii, p. 327.Google Scholar
48 Orestano, G.—“Azione dei farmaci del gruppo della canfora sul respiro periodico de cocaina,” Arch. Internat, de Pharmacodyn. et de Thérapie, 1928, xxxv, p. 351.Google Scholar
49 Schlaepfer, K.—“Antagonistic Effect of Metrazol to Shock and Anaesthetic Depression,” Anæsth. and Analg., 1936, xv, p. 202.Google Scholar
50 Gros, O.—“Beitrag zum gegenseitigen Antagonismus zwischen Cardiazol,. Coramin Und Narkotica,” Arch. f. exp. Path. u. Pharm., 1936, clxxx, p. 258.CrossRefGoogle Scholar
51 Idem and Haas, H. T. A.—“Der Antagonismus der Narkotica gegen Cardiazol,” ibid., 1936, clxxxii, p. 348.Google Scholar
52 Lendle, L.—“Vergleichende Untersuchung über die Wirkungsbedingungen von Cardiazol und Coramin im Tierversuch,” ibid., 1936, clxxxi, p. 408.Google Scholar
53 Zipf, K., and Hoppe, H.—“Die Entgiftung von Lokalanæsthetika durch Cardiazol,” ibid., 1936, clxxxiii, p. 67.Google Scholar
54 Albus, G.—“Tierexperimentelle Untersuchungen über die Weckwirkung handelsüblicher Analeptica unter besonderer Berucksichtigung von Cardiazol und Coramin,” ibid., 1936, clxxxii, p. 471.Google Scholar
55 Koll, W.—“Studien über den Antagonismus von Narkotica und Analeptica am Zentralnervensystem,” ibid., 1937, clxxxiv, p. 365.Google Scholar
56 von Nyary, A.—“Die krampfhemmende Wirkung der Hypnotika,” ibid., 1932, clxv, p. 504.Google Scholar
57 Jackson, D. E.—“Variations in Reaction of Different Parts of the Central Nervous System as Influenced by Depressant and Stimulating Drugs,” Journ. of Lab. and Clin. Med., 1934, xx, p. 1.Google Scholar
58 Biehler, W.—“Krampfgrenze und Krampfhemmung,” Arch. f. exp. Path. u. Pharm., 1935, clxxviii, p. 693.Google Scholar
59 Zipf, K., Windshus, W. A., and Kokoschka, F.—“Zur Wirkung von Cardiazol, Coramin, Hexeton, Strychnin und Ikoral gegenüber Narkotica,” ibid., 1937, clxxxv, p. 113.Google Scholar
60 Hoffman, H.—“Beeinflussung des Blutdrucks durch Cardiazol und Ephedrin an Tieren, die mit Schlafmitteln vorbehandelt wurden,” ibid., 1936, clxxxiii, p. 146.Google Scholar
61 Labes, R., Wedell, K., and Soehring, K.—“Beziehungen zwischen der Wirkung von Krampfgiften und Störungen der Gewebsatmung,” ibid., 1937, clxxxv, p. 379.Google Scholar
62 Flossbach, F., and Weber, E.—“Untersuchungen über Verweildauer und Konzentration von Chinin im Blut in der Kombination Cardiazol-Chinin,” Fortsch. d. Therap., 1936, xii, p. 526.Google Scholar
63 Johnston, C.—“Cardiazol, A Clinical Report,” Bull. Johns Hopkins Hosp., 1929, xliv, p. 32.Google Scholar
64 Zunz, E., and Tremonti, P.—“Recherches sur l'action de la coramine et du pentamethylènetètrazol sur la respiration,” Arch. Internat, de Pharmacodyn. et de Thérapie, 1931, xli, p. 1.Google Scholar
65 Rice, J. C., and Isenberger, R. M.—“Pharmacodynamic Reactions of Intracisternal Sodium Isoamylethylbarbiturate (Sodium Amytal), Pyridine-beta-carbonic Acid Diethylamide (Coramine), Pentamethylene-tetrazol (Metrazol) and Picrotoxin during Morphine-Sodium Isoamylethylbarbiturate Anæsthesia,” Journ. Pharm. and Exper. Therap., 1937, lix, p. 43.Google Scholar
66 de Morsier, G., Georgi, F., and Rutishauer, G.—“Étude experimentale des convulsions produites par le cardiazol chez le lapin,” Therapie der Schizophrenie, suppl. Schweiz. Arch. f. Neur. u. Psychiat., 1937, xxxix, p. 144.Google Scholar
67 Stender, A.—“Über Provokation Epileptiformer Anfälle durch Cardiazol,” Münch, med. Wochenschr., 1937, lxxxiv, p. 1893.Google Scholar
68 Langeluddeke, A.—“Die diagnostische Bedeutung experimentell erzeugter Krampfe,” Deutsch, med. Wochenschr., 1936, lxii, p. 1588.Google Scholar
69 Schönmehl, . —“Provokation von epileptischen Krampfanfällen. Versuche und Ausblick,” Münch, med. Wochenschr., 1936, lxxxiii, p. 721.Google Scholar
70 Stern, R.—“Zur Differentialdiagnose der Epilepsie,” ibid., 1937, lxxxiv, p. 177.Google Scholar
71 Grubel, R.—“Der Wert der Auslösung von Cardiazolkrämpfen fur die Erbgesundheitspflege,” ibid., 1937, lxxxiv, p. 469.Google Scholar
72 Kruger, L.—“Beitrag zur Frage der Schizophreniebehandlung nach v. Meduna,” Psychiat.-Neurol. Wochenschr., 1936, xxxviii, p. 135.Google Scholar
73 Janz, H. W.—“Die diagnostischen Verwertbarkeit der Cardiazolkrampfe,” Münch. med. Wochenschr., 1937, lxxxiv, p. 471.Google Scholar
74 Voss, J.—“Pentamethylenetetrazol (Cardiazol),” Arch. f. exp. Path. u. Pharm., 1926, cxviii, p. 259.Google Scholar
75 Wortis, S. B., Coombs, H. C., and Pike, F. H.—“Monobromated Camphor: A Standardized Convulsant,” Arch. Neurol. and Psychiat., 1931, xxvi, p. 156.Google Scholar
76 Coombs, H. C., and Pike, F. H.—“Respiratory and Cardiovascular Changes in the Cat during Convulsions of Experimental Origin,” Amer. Journ. Physiol., 1931, xcvii, p. 92.Google Scholar
77 Coombs, H. C., and Cope, O. M.—“Arrest of Experimental Convulsions by Acetylcholine in the Cat,” Proc. Soc. Exper. Biol, and Med., 1936, xxxiv, p. 483.Google Scholar
78 Denny-Brown, D., and Robertson, E. G.—“Observations on Records of Local Epileptic Convulsions,” Journ. Neur. and Psychopath., 1934, xv, p. 97.Google Scholar
79 Gibbs, F. A., Lennox, W. G., and Gibbs, E. L.—“Cerebral Blood Flow Preceding and Accompanying Epileptic Seizures in Man,” Arch. Neur. and Psychiat., 1934, xxxii, p. 257.Google Scholar
80 Drabkin, D. L., and Ravdin, I. S.—“The Mechanism of Convulsions in Insulin Hypoglycæmia,” Amer. Journ. Physiol., 1937, cxviii, p. 174.Google Scholar
81 Spiegel, E., and Spiegel-Adolf, M.—“Physico-chemical Mechanisms in Convulsive Reactivity,” Proc. Soc. Exper. Biol, and Med., 1936, xxxiv, p. 799.Google Scholar
82 Asher, L., and Takahashi, K.—“On the Experimental Production of Lack of Carbohydrates and on the Carbohydrate Mechanism of the Central Nervous System,” ibid., 1925, xxii, p. 238.Google Scholar
83 Himwich, H. E., and Nahum, L. H.—“The Respiratory Quotient of Brain,” Amer. Journ. Physiol., 1929, xc, p. 389.Google Scholar
84 Holmes, E. G.—“The Relation between Carbohydrate Metabolism and the Function of the Grey Matter of the Central Nervous System,” Biochem. Journ., 1933, xxvii, p. 523.Google Scholar
85 Prados y Such, M.—“Untersuchungen über Epilepsie. Die Bluthirnschranke und der experimentelle Krampfanfall,” Arch. f. Psychiat., 1936, cv, p. 17.Google Scholar
86 von Meduna, L.—“Die Bedeutung des epileptischen Anfalls in der Insulin und Cardiazolbehandlung der Schizophrenie,” Psychiat. Neurol. Wochenschr., 1937, xxxix, p. 331.Google Scholar
87 Idem, . —Die Konvulsionstherapie der Schizophrenie, Carl Marhold, Halle a S., 1937.Google Scholar
88 Idem. —“New Methods of Medical Treatment of Schizophrenics,” Arch. Neur. and Psychiat., 1936, xxxv, p. 361.Google Scholar
89 Kennedy, A.—“Convulsion Therapy in Schizophrenia,” Journ. Ment. Sci., 1937, xxxiii, p. 609.Google Scholar
90 Cook, L. C.—“Convulsion Therapy in Schizophrenia,” Proc. Roy. Soc. Med., 1938, xxxi, p. 567.Google Scholar
91 Georgi, F., and Strauss, R.—“Krampfproblem und Insulintherapie. Besondere Berücksichtigung des von Meduna angegeben Verfahrens,” Therapie der Schizophrenie, suppl. Schweiz. Arch. f. Neurol. u. Psychiat., 1937, xxxix, p. 55.Google Scholar
92 Frisch, F., and Weinberger, W.—“Untersuchungen bei periodischer Epilepsie,” Zeitschr. f. d. ges. Neur. u. Psychiat., 1922, lxxix, p. 576.Google Scholar
93 Frisch, F., and Fried, E.—“Zur Frage der engeblichen Alkalose bei Epilepsie,” Zeitschr. f. d. ges. Exper. Med., 1926, xlix, p. 462.Google Scholar
94 Gamble, J. L., and Hamilton, B.—“The Acid-base Composition of Urine from an Epileptic,” Bull. Johns Hopkins Hosp., 1927, xli, p. 389.Google Scholar
95 Byrom, F. B.—“A Study of the Total Exchange of Water, Sodium, Potassium and Nitrogen in Epilepsy,” Quart. Journ. Med., 1932, xxv (n.s.i), p. 289.Google Scholar
96 Ostmann, . —“Renale Kochsalzausschiedung und epileptischer Krampfanfall,” Allg. Zeitschr. f. Psychiat., 1934, ci, p. 301.Google Scholar
97 Georgi, F.—“Humoralpathologische Bemerkungen zur Insulinschocktherapie bei Schizophrenen,” Schweiz, med. Wochenschr., 1936, lxvi, p. 935.Google Scholar
98 Gross, M.—“Insuline et Schizophrénie,” ibid., 1936, lxvi, p. 689.Google Scholar
99 Heilbrunn, G.—“Zur Frage der parasympathikotonischen oder sympathikotonischen Umstellung des Organismus während der Insulinschockbehandlung der Schizophrenie,” ibid., 1936, lxvi, p. 961.Google Scholar
100 Lennox, W. G., and Cobb, S.—Epilepsy, Baillière, Tindali & Cox, London, 1928.Google Scholar
101 Guirdham, A., and Pettit, A. W.—“Hæmatology of Convulsions,” Journ. Ment. Sci., 1937, lxxxii, pp. 371 and 700.Google Scholar
102 Muller, E. F., and Myers, C. N.—“Biochemical Studies on the Behaviour of the Leucocytes after Intravenous Administration of Alkalinized Salvarsan,” Proc. Soc. Exper. Biol, and Med., 1924, xxii, p. 95.Google Scholar
103 Muller, E. F.—“The Involuntary Nervous System: An Important Factor in the Body's Resistance,” Arch. Int. Med., 1925, xxxv, p. 796.Google Scholar
104 Bömer, M. I.—“Uber die Wirkung einiger Krampfgifte auf Blutzucker und Blutmilchsaüre,” Arch. f. exp. Path. u. Pharm., 1930, cxlix, p. 247.Google Scholar
105 Demole, V., and Bersot, H.—“Choc ‘insulinique’ et choc ‘analeptique’ chez le lapin,” Therapie der Schizophrenie, suppl. Schweiz. Arch. f. Neurol. u. Psychiat., 1937, xxxix, p. 108.Google Scholar
106 Georgi, F.—“Krampfproblem und Insulintherapie. Berücksichtigung klinischer und humoralpathologischer Gesichtspunkte,” ibid., 1937, xxxix, p. 49.Google Scholar
107 Homstron, R.—“Blutzuckerbestimmungen bei Epileptikern,” Upsala Lakaref Forh., 1924, lxxix, p. 17.Google Scholar
108 Lennox, W. G., O'Connor, M., and Bellinger, M.—“Studies of the Metabolism in Epilepsy. 2: The Sugar Content of the Blood,” Arch. Neur. and Psychiat., 1927, xviii, p. 383.Google Scholar
109 Kersten, H.—“Ergebnisse zur Frage des elementaren Krampfes,” Zeitschr. f. d. ges. Neur. u. Psychiat., 1921, lxii, p. 48.CrossRefGoogle Scholar
110 Cannon, W. B.—Bodily Changes in Pain, Hunger, Fear and Rage, Appleton, New York, 1929.Google Scholar
111 Hrubetz, C. M.—“The Blood-sugar Level after Administration of Physostigmine and Atropine,” Amer. Journ. Physiol., 1937, cxviii, p. 301.Google Scholar
112 Idem. —“The Blood-sugar Level after Administration of Pilocarpine, Atropine and Acetylcholine,” ibid., 1936, cxiv, p. 551.Google Scholar
113 Nitescu, I., and Benetato, G. R.—“Action des substances parasympathicotropes sur le sucre protéidique du sang,” Compt. Rend. Soc. Biol., 1932, cix, p. 1005.Google Scholar
114 MacGuignan, H.—“The Influence of Atropine and Pilocarpine on the Glycogenic Function,” Journ. Pharm. Exper. Therap., 1916, viii, p. 407.Google Scholar
115 Dale, H. H., and Laidlaw, P. P.—“The Significance of the Suprarenal Capsules in the Action of Certain Alkaloids,” Journ. Physiol., 1912, xlv, p. 1.Google Scholar
116 Stewart, G. N. and Rogoff, J. M.—“The Action of Drugs on the Output of Epinephrine from the Adrenals,” Journ. Pharm. Exper. Therap., 1920, xvi, p. 71.Google Scholar
117 Briner, O.—“Ergebnisse der Konvulsionstherapie an der Psychiatrischen Klinik in Bern,” suppl. Schweiz. Arch. f. Neurol. u. Psychiat., 1937, xxxix, p. 118.Google Scholar
118 von Meduna, L.—“Allgemeine Betrachtungen über die Cardiazoltherapie,” ibid., 1937, xxxix, p. 32.Google Scholar
119 Kretschmer, E.—Physique and Character, Kegan Paul, London, 1936.Google Scholar
120 Grundler, W.—“Über Konstitutionsuntersuchungen an Epileptischen,” Monatsschr. f. Psychiat. u. Neurol., 1926, lx, p. 216.Google Scholar
121 Notkin, J.—“Epileptic Manifestations in the Group of Schizophrenic and Manic-depressive Psychoses,” Journ. Nerv. and Ment. Dis., 1929, lxxix, p. 494.Google Scholar
122 Falsey, E. F.—“Typical Epileptic Seizures in the Course of Schizophrenia: A Report of Two Cases,” New England Journ. Med., 1935. ccxii, p. 153.Google Scholar
123 Vorkastner, W.—“Epilepsie und Dementia præcox,” suppl. Monatsschr. f. Neurol. u. Psychiat., Berlin, Karger, 1918.Google Scholar
124 Gruhle, H. W.—“Über den Wahn bei Epilepsie,” Zeitschr. f. d. ges. Neur. u. Psychiat., 1935, cliv, p. 395.Google Scholar
125 Kraepelin, E.—Dementia Præcox and Paraphrenia, Edinburgh, Livingstone, 1919.Google Scholar
126 Jeliffe, S. E., and White, W. A.—Diseases of the Nervous System, London, Lewis, 1925.Google Scholar
127 Galloway, J. H. W., Kaye, , et al.—Report upon the Physical Examination of Men of Military Age. London: H.M. Stationery Office, vol. i, 1920.Google Scholar
128 Bowman, K. M., Eidson, J. P., and Burladge, S. P.—“Biological Studies in Ten Cases of Dementia Præcox,” Boston Med. and Surg. Journ., 1921, clxxxvii, p. 358.Google Scholar
129 Bowman, K. M., and Grabfield, G. P.—“Basal Metabolism in Mental Disease,” Arch. Neur. and Psychiat., 1923, ix, p. 358.Google Scholar
130 Gibbs, C. E., and Lemke, D. E.—“Study in Basal Metabolism in Dementia Præcox and Manic-depressive Psychoses,” Arch. Int. Med., 1923, xxxi, p. 102.Google Scholar
131 Farr, C. B.—“Results of Basal Metabolism Tests in 100 Mental Cases,” Arch. Neur. and Psychiat., 1924, xii, p. 518.Google Scholar
132 Hoskins, R. G., and Sleeper, F. H.—“Basal Metabolism in Schizophrenia,” ibid., 1929, xxi, p. 887.Google Scholar
133 Hoskins, R. G., and Walsh, A.—“Oxygen Consumption (Basal Metabolic Rate) in Schizophrenia,” ibid., 1932, xxviii, p. 1346.Google Scholar
134 Löwenbach, H.—“Messende Untersuchungen über die Erregbarkeit der Zentralnervensystems von Geisteskranken, von allem von periodisch Katatonen, mit Hilfe quantitativen Vestibularisreizung,” Arch. f. Psychiat., 1936, cv, p. 313.Google Scholar
135 Wuth, O.—“Die Blutzucker bei Psychosen,” Zeitschr. f. d. ges. Neur. u. Psychiat., 1921, lxiv, p. 83.Google Scholar
136 Newcomen, H. S.—“Blood Constituents and Mental State,” Amer. Journ. Psychiat., 1922, i, p. 609.Google Scholar
137 Weston, P. G.—“Analysis of the Blood of Insane Patients,” Arch. Neur. and Psychiat., 1920, iii, p. 147.Google Scholar
138 Mumford, P. B., and Parkin, G. G.—“Some Observations on the Fasting Blood sugar in Certain Mental States,” Journ. Ment. Sci., 1923, lxix, p. 330.Google Scholar
139 Uyematsu, S., and Soda, T.—“Blood Analyses in Cases of Catatonic Dementia præcox,” Journ. Nerv. and Ment. Dis., 1921, liii, p. 367.Google Scholar
140 Roggenbau, C.—“Zur Frage der körperlichen Störungen der endogenen Psychosen und ihrer Werwertbarkeit in differentialdiagnostischer Hinsicht,” Monatsschr. f. Psychiat., 1936, xcii, p. 243.Google Scholar
141 Reiter, P. J.—“Über Störungen des Zuckerstoffwecksels bei Geisteskranken, insbesonder bei Syntonen,” Zeitschr. f. d. ges. Neur. y. Psychiat., 1923, lxxxvii, p. 179.Google Scholar
142 Janney, N., and Isaacson, V. A.—“Blood-sugar Tolerance Test,” Journ. Amer. Med. Assoc., 1918, lxx, p. 1131.Google Scholar
143 Kooy, F. H.—“Hyperglycæmia in Mental Disorders,” Brain, 1919, xlii, p. 214.Google Scholar
144 Raphael, T., and Parsons, J. P.—“Blood-sugar Studies in Dementia Præcox and Manic-depressive Insanity,” Arch. Neur. and Psychiat., 1921, v, p. 687.Google Scholar
145 Lorenz, W. F.—“Sugar Tolerance in Dementia Præcox and other Mental States,” ibid., 1922, viii, p. 184.Google Scholar
146 Schwab, S. J.—“Diagnostic Value of Blood-sugar Curves in Neurology,” ibid., 1922, viii, p. 401.Google Scholar
147 Henry, G. W., and Mangam, E.—“Blood in Personality Disorders,” ibid., 1922, viii, p. 184, and 1925, xiii, p. 743.Google Scholar
148 Schryver, D.—“Blutzucker und Schizophrenie,” Zeitschr. f. d. ges. Neur. Psychiat., 1923, lxxxvii, p. 179.Google Scholar
149 Barrett, T. M., and Serre, D.—“Blood Analysis and Sugar Tolerance Tests in Mental Disease,” Journ. Nerv. and Ment. Dis., 1924, lix, p. 561.Google Scholar
150 Drury, K. K., and Farran Ridge, C.—“Some Observations on the Types of Blood-sugar Curve Found in Different Forms of Insanity,” Journ. Ment. Sci., 1925, lxxi, p. 8.Google Scholar
151 Mann, S. A.—“Blood-sugar Studies in Mental Disorders,” ibid., 1925, lxxi, p. 443.Google Scholar
152 Kasanin, J.—“The Blood-sugar Curve in Mental Disease. 2. The Schizophrenic (Dementia praecox) Group,” Arch. Neur. and Psychiat., 1926, xvi, p. 414.Google Scholar
153 Smith, J. F., and Hill, H. G.—“The Blood-sugar Curve in Dementia Præcox,” Journ. Ment. Sci., 1927, lxxiii, p. 265.Google Scholar
154 Di Mauro, S.—“La courbe de la glycémie dans la schizophrénie,” L'Encéphale, 1936, xxxi, No. 2, p. 356.Google Scholar
155 Raphael, T., and Parsons, J. P.—“Metabolism Studies in Dementia Præcox and Manic-depressive Insanity: Glycemic Reactions to the Intramuscular Administration of Epinephrine,” Arch. Neur. and Psychiat., 1922, viii, p. 172.Google Scholar
156 Gordon, H., Ostrander, J., and Counsell, S.—“The Adrenalin Glycæmic Curve as a Diagnostic Aid in Psychiatry,” Amer. Journ. Psychiat., 1927, vii, p. 183.Google Scholar
157 Appel, K. E., and Palmer, H. D.—“Ephedrine Circulatory and Glycæmic Reactions in the Psychoses,” Arch. Neur. and Psychiat., 1932, xxvii, p. 129.Google Scholar
158 Schulze-Bunte, . —“Über den Einfluss des Adrenalins auf den Blutzucker bei Schizophrenen,” Monatsschr. f. Psychiat. u. Neurol., 1936, xciv, p. 113.Google Scholar
159 Claude, H., Santenoise, D., and Targowla, R.—“An Attempt at Biological Diagnosis of States of Excitement and Depression,” Arch. Neur. and Psychiat., 1925, xiii, p. 729.Google Scholar
160 Hoskins, R. G., and Sleeper, F. H.—“Galactose Tolerance in Dementia Præcox,” ibid., 1930, xxiv, p. 550.Google Scholar
161 Rowe, A. W.—“Sugar Tolerance as an Aid to Diagnosis,” Journ. Amer. Med. Assoc., 1927, lxxxix, p. 1403.Google Scholar
162 Nielsen, J. M.—“Convulsions of Undetermined Ætiology; Studies of the Blood-sugar,” Arch. Neur. and Psychiat., 1934, xxxi, p. 1055.Google Scholar
163 Lennox, W. G., O'Connor, M., and Bellinger, M.—“Chemical Changes in the Blood during Fasting in the Human Subject,” Arch. Int. Med., 1926, xxxviii, p. 553.Google Scholar
164 Lennox, W. G., and Bellinger, M.—“Studies of the Metabolism in Epilepsy: III. The Blood-sugar Curve,” Arch. Neur. and Psychiat., 1927, xviii, p. 395.Google Scholar
165 Münch-Petersen, C. J., and Schön, H. I.—“Investigations into Sugar Metabolism in Epileptics, especially the Sugar Threshold in Adrenalin and Glucose Hyperglycæmia,” Acta Psychiat. et Neurol., 1931, vi, p. 545.Google Scholar
166 Minchin, R. L. H.—“Factor of Hypoglycæmia in the Ætiology of Idiopathic Epilepsy,” Journ. Ment. Sci., 1933, lxxix, p. 659.Google Scholar
167 Drewry, H. H. A.—“A Study of Sugar Tolerance Tests in 200 Patients with Convulsions,” Bull. Neurol. Inst. New York, 1937, vi, p. 62.Google Scholar
168 Mann, S. A., and Marsh, R. G. B.—“The Significance of Urinary Reaction in Psychotic Subjects,” Journ. Ment. Sci., 1928, lxxiv, p. 436.Google Scholar
169 Golla, F., Mann, S. A., and Marsh, R. G. B.—“The Respiratory Regulation in Psychotic Subjects,” ibid., 1928, lxxiv, p. 443.Google Scholar
170 Mann, S. A.—“The Neutral Sulphur Excretion in Dementia Præcox following Sodium Thiosulphate Ingestion,” Journ. Ment. Sci., 1925, lxxi, p. 284.Google Scholar
171 Loewenhardt, A. S., Lorenz, W. F., and Waters, R. M. J.—“Cerebral Stimulation,” Journ. Amer. Med. Assoc., 1929, xcii, p. 880.Google Scholar
172 Loewenhardt, A. S., Lorenz, W. F., Martin, H. G., and Malone, J. Y.—“Stimulation of the Respiration by Sodium Cyanide and its Clinical Application,” Arch. Int. Med., 1918, xxi, p. 109.Google Scholar
173 Looney, J. M., and Childs, H. M.—“The Lactic Acid and Glutathione Content of the Blood of Schizophrenic Patients,” Journ. Clin. Invest., 1934, xiii, p. 963.Google Scholar
174 Hoskins, R. G.—“Oxygen Metabolism in Schizophrenia,” Arch. Neur. and Psychiat., 1937, xxxviii, p. 1261.Google Scholar
175 MacFarland, R. A.—“Psychological Effects of Oxygen Deprivations,” Arch. Psychol., 1932, i, p. 145.Google Scholar
176 Jowett, M., and Quastel, J. H.—“The Effect of Narcotics on Tissue Oxidations,” Biochem. Journ., 1937, xxxi, p. 565.Google Scholar
177 Thompson, J. W., Corwin, W., and Aste-Salazar, J. H.—“Physiological Patterns and Mental Disturbance,” Nature, 1937, cxl, p. 1062.Google Scholar
178 Freeman, H.—“The Arm-to-Carotid Circulation Time in Normal and Schizophrenic Subjects,” Psychiatric Quart., 1934, viii, p. 290.Google Scholar
179 Finesinger, J. E., Cohen, M. E., and Thompson, K. J.—“Velocity of Blood-flow in Schizophrenia,” Arch. Neur. and Psychiat., 1938, xxxix, p. 24.Google Scholar
180 Pickworth, F. A.—“A New Outlook on the Physiology and Pathology of Mental and Emotional States,” Brit. Med. Journ., 1938, p. 265.Google Scholar
181 Hallay, L.—“Massage of the Brain in Schizophrenia,” Med. Record, 1936, cxliii, p. 382.Google Scholar
182 Katzenelbogen, S., and Goldsmith, H.—“The Distribution of Calcium between Blood and Cerebro-spinal Fluid in Mental Diseases,” Amer. Journ. Psychiat., 1931, xi, p. 9.Google Scholar
183 Idem. —“The Hæmato-encephalic Barrier. The Diagnostic Value of Walter's Bromide Test in Mental Diseases,” ibid., 1931, x, p. 1045.Google Scholar
184 Hauptman, A.—“Die Verminderte Durchlässigkeit der Blut-Liquor Schranke bei Schizophrenie,” Monatsschr. f. Psychiat. u. Neurol., 1928, lxviii, p. 243.CrossRefGoogle Scholar
185 Malamud, W., Fuchs, D., and Malamud, N.—“Barrier between the Blood and Cerebro-spinal Fluid. Changes in Permeability in Mental Diseases,” Arch. Neur. and Psychiat., 1928, xx, p. 780.Google Scholar
186 Malamud, W., and Rothschild, D.—“Barrier between the Blood and Cerebro-spinal Fluid. Distribution Ratio of Bromides in Schizophrenics,” ibid., 1930, xxiv, p. 348.Google Scholar
187 Stief, A.—“Der Wirkungsmechanismus der sogenannten Konvulsionstherapien mit besonderer Rücksicht auf die Insulinschockbehandlung,” Psychiat. Neurol. Wochenschr., 1937, xxxix, p. 225.Google Scholar
188 Pfister, H. O.—“Die neuro-vegetativen Störungen der Schizophrenen und ihre Beziehungen zur Insulin- Cardiazol- und Schlafkurbehandlung,” Therapie der Schizophrenie, suppl. Schweiz. Arch. f. Neurol. u. Psychiat., 1937, xxxix, p. 77.Google Scholar
189 Schmidt, V.—“Adrenalinunempfindlichkeit der Dementia Præcox,” Münch. med. Wochenschr., 1914, vii, p. 367.Google Scholar
190 Schultz, . —“Neue körperliche Symptome bei Dementia Præcox,” ibid., 1914, vii, P. 1759.Google Scholar
191 Dawson, W. S.—“A Study of the Endocrine-autonomic Disorders of Dementia Præcox,” Journ. Ment. Sci., 1923, lxix, p. 183.Google Scholar
192 Kanner, L.—“The Adrenalin Blood-pressure Curves in Dementia Præcox and the Emotional Psychoses,” Amer. Journ. Psychiat., 1928, viii, p. 75.Google Scholar
193 Freeman, H., and Carmichael, H. T.—“A Pharmacodynamic Investigation of the Autonomic Nervous System in Schizophrenia. I: Effect of Intravenous Injection of Epinephrine on the Blood-pressure and Pulse-rate,” Arch. Neur. and Psychiat., 1935, xxxiii, p. 342.Google Scholar
194 Biller, D.—Uber die Wirkung des Adrenalins mit besonderer Berücksichtigung der Dementia Præcox, Bonn, 1915.Google Scholar
195 Severin, G.—“Über Adrenalinwirkung bei Schizophrenen und Gesunden,” Monatsschr. f. Psychiat. u. Neurol., 1916, xl, p. 265.Google Scholar
196 Sierra, A. M.—“Physiologic Tests in the Insane,” Semana Med., 1923, i, p. 3; abstr. Journ. Amer. Med. Assoc., 1923, lxxx, p. 967.Google Scholar
197 Lowry, L. G., and Wright, W. W.—“The Effect upon the Blood-pressure of the Injection of Adrenalin in Dementia Præcox,” Boston Med. and Surg. Journ., 1920, clxxxiii, p. 209.Google Scholar
198 Northcote, M. L. M.—“The Clinical Investigation of the Autonomic Nervous System in 50 Cases of Schizophrenia,” Journ. Ment. Sci., 1929, lxxv, p. 114.Google Scholar
199 Gillespie, R. D.—“The Variability of the Blood-pressure in some Morbid Conditions,” ibid., 1926, lxxii, p. 325.Google Scholar
200 Hoskins, R. G., and Sleeper, F. H.—“Organic Functions in Schizophrenia,” Arch. Neur. and Psychiat., 1933, xxx, p. 123.Google Scholar
201 Gottlieb, J. S., and Linder, F. E.—“Body Temperatures of Persons with Schizophrenia and of Normal Subjects: Effect of Changes in Environmental Temperature,” ibid., 1935, xxxiii, p. 775.Google Scholar
202 Gottlieb, J. S.—“Relationship of Systolic to Diastolic Blood-pressure in Schizophrenia; Effect of Environmental Temperature,” ibid., 1936, xxxv, p. 1256.Google Scholar
203 Finklemann, I., and Stephens, W. M.—“Heat Regulation; Reaction of Patients to Cold,” Journ. Neur. and Psychopath., 1936, xvi, p. 321.Google Scholar
204 Katzenelbogen, S.—“Schizophrenia; Chemical Analyses of Blood and Cerebro-spinal Fluid,” Arch. Neur. and Psychiat., 1937, xxxvii, p. 881.Google Scholar
205 Monnier, M.—“Der Dauerschlafbehandlung der Schizophrenien mit der Narkosenmischung von Cloetta an der Psychiatrischen Klinik Burghölzli-Zurich,” Nervenarzt, 1936, ix, p. 14.Google Scholar
206 McCowan, P. K.—“The Physico-psycho-galvanic Reflex in the Neuroses and Psychoses,” Journ. Ment. Sci., 1926, lxxii, p. 492.Google Scholar
207 Sakel, M.—Neue Behandlung der Schizophrenie, Vienna, 1935.Google Scholar
208 Hoskins, R. G., and Sleeper, F. H.—“A Metabolic Study of Desiccated Suprarenal Medication,” Endocrinology, 1930, xiv, p. 109.Google Scholar
209 Hoskins, R. G., and Freeman, H.—“Some Effects of a Glycerine Extract of Suprarenal Cortex Potent by Mouth,” ibid., 1933, xvii, p. 29.Google Scholar
210 Idem. —“Comparative Sensitiveness of Schizophrenic and Normal Subjects to Glycerine Extract of Adrenal Cortex,” ibid., 1934, xviii, p. 576.Google Scholar
211 Idem. —“Weight Changes Following use of Glycerine Extract of Adrenal Cortex,” ibid., 1936, xx, p. 565.Google Scholar
212 Freeman, H., Linder, F. E., and Hoskins, R. G.—“Further Studies on a Glycerine Extract of Adrenal Cortex by Mouth,” ibid., 1933, xvii, p. 677.Google Scholar
213 Humbert, F., and Friedemann, A.—“Critiques et indications des thérapeutiques de la schizophrenie.” Therapie der Schizophrenie, suppl. Schweiz. Arch. f. Neurol. u. Psychiat., 1937, xxxix, p. 123.Google Scholar
214 Gillies, H.—“Convulsive Therapy in Schizophrenia,” Lancet, 1937, ii, p. 131.Google Scholar
215 Boss, M.—“Die psychische Dynamik der Schlafkur bei Schizophrenen,” Schweiz. Arch. f. Neurol. u. Psychiat., 1935, xxxvi, p. 209.Google Scholar
216 Angyal, L. von, and Gyarfas, K.—“Über die Cardiazol-Krampfbehandlung der Schizophrenie,” Arch. f. Psychiat., 1936, cvi, p. 1.Google Scholar
217 Wahlman, . —“Vorläufige Mitteilung über Konvulsionstherapie der Psychosen,” Psychiat. Neurol. Wochenschr., 1936, xxxviii, p. 78.Google Scholar
218 Gulotta, S.—“La cura della schizofrenia con la provocazione di convulsioni epilet. tiche,” Riv. Sper. di Freniat., 1936, lx, p. 510.Google Scholar
219 Finiefs, L. A.—“Induced Epileptiform Attacks as a Treatment of Schizophrenia,” Lancet, 1937, ii, p. 131.Google Scholar
220 Scheuhammer, P., and Wisgott, L.—“Erfahrungen mit der Cardiazolbehandlung der Schizophrenie,” Psychiat. Neurol. Wochenschr., 1937, xxxix, p. 286.Google Scholar
221 Dhunjibhoy, J. E.—“Treatment of Schizophrenia by Induced Convulsions,” Lancet, 1938, i, p. 370.Google Scholar
222 Strecker, H. P.—“A Comparison of Insulin and Cardiazol Convulsion Therapies in the Treatment of Schizophrenia,” Lancet, 1938, i, p. 371.Google Scholar
223 Henderson, D. K., and Gillespie, R. D.—A Textbook of Psychiatry, Oxford University Press, 1936.Google Scholar
224 Wortis, J.—“Response of Schizophrenic Subjects to Hypoglycæmic Insulin Shock,” Journ. Nerv. and Ment. Dis., 1936, lxxxiv, p. 497.Google Scholar
225 Gjessing, R.—“Beiträge zur Kenntnis der Pathophysiologie des katatonen Stupors,” Arch. f. Psychiat., 1932, xcvi, p. 319.Google Scholar
226 Lennox, W. G., and Wright, L. H.—“Studies in Epilepsy: The Basal Metabolism,” Arch. Neur. and Psychiat., 1928, xx, p. 764.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.